MCA Stability Tool

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Accord-UK Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Amarox Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Aspire Pharma Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Bristol Laboratories Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Crescent Pharma Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (HBS Healthcare Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Key Pharmaceuticals Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Krka UK Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Macleods Pharma UK Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Aripiprazole 30mg tablets (Medical Valley Invest AB)

Explore other Aripiprazole formulations Explore other Aripiprazole 30mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 30mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 30mg tablets (Aurobindo Pharma - Milpharm Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.